OrbiMed Raises $3 Billion for Global and Asian Private Equity Funds
OrbiMed Secures $3 Billion for New Private Equity Funds
On October 15, 2026, OrbiMed, a leading global investment firm specializing in healthcare, announced the successful capital commitments of $3 billion for two new private equity funds, namely, OrbiMed Private Investments X and OrbiMed Asia Partners VI. This significant funding is earmarked for investments in the field of life sciences and healthcare.
Details of the Investment Funds
The OrbiMed Private Investments X fund has successfully raised over $1.9 billion, specifically aimed at venture capital investments within the life sciences sector across the United States and Europe. This fund strives to identify and cultivate groundbreaking healthcare companies focusing on biopharmaceuticals, medical devices, diagnostics, and technology-enabled services.
In parallel, OrbiMed Asia Partners VI has raised more than $1 billion for growth equity and venture capital investments within the Asian healthcare landscape. OrbiMed is dedicated to shaping the future of healthcare by investing in innovative companies that have the potential to revolutionize the industry.
Transformational Opportunities in Healthcare
Carl Gordon, one of the managing partners at OrbiMed, expressed enthusiasm regarding the current investment climate in life sciences, stating, "There has never been a more exciting time to invest in innovation within the life sciences. The rise of AI, the surge in new therapeutic modalities, and China's emergence as a biotech powerhouse are expanding the opportunities to develop transformative therapies. We look forward to aiding entrepreneurs in converting these advancements into leading healthcare companies." This statement underlines the optimism surrounding technological advancements and innovative practices that are set to define the future of healthcare.
OrbiMed's Strength and Global Reach
OrbiMed operates under the leadership of 20 partners and is supported by a dedicated team of over 150 professionals with expertise in business incubation, strategy, operations, and finance. With a presence in 12 major healthcare markets globally, OrbiMed is well-positioned to execute investments and drive growth in the healthcare sector.
The investors contributing to these newly launched funds include a diverse range of institutional medical organizations, university endowments, foundations, pension funds, sovereign wealth funds, and family offices. Carter Neild, also a managing partner at OrbiMed, conveyed gratitude for the continuous support from their longstanding investors, promising to work diligently to meet their high expectations in the forthcoming years.
About OrbiMed
Founded with the vision of serving as a leading partner in healthcare investment, OrbiMed boasts over $21 billion in assets under management. The firm engages in investing throughout the healthcare spectrum, from startups to established multinational corporations, employing private equity funds, public equity funds, and royalty/credit funds. To learn more about OrbiMed and explore opportunities for innovative healthcare solutions, visit www.orbimed.com.
The announcement heralds a significant step for OrbiMed in its journey to enhance healthcare innovation while reinforcing its role as a pivotal investor in the healthcare sector globally.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.